Clinical Breakpoint of Apramycin to Swine Salmonella and Its Effect on Ileum Flora

Xinyu Dai, Yufeng Gu, Jinli Guo, Lingli Huang, Guyue Cheng, Dapeng Peng, Haihong HaoInternational Journal of Molecular Sciences 2022 · DOI

TL;DR

This study establishes the clinical breakpoint (CBP) for apramycin (APR) against swine Salmonella, setting a crucial standard for antibiotic susceptibility testing. It also reveals how APR treatment impacts the ileum's microbial community in diarrheic piglets, highlighting shifts in key bacterial genera and metabolic pathways.

What Problem Does This Paper Address?

Salmonella infections in pigs are a significant concern for animal health and food safety. While apramycin (APR) is a veterinary antibiotic used to combat Gram-negative bacteria like Salmonella, there was a lack of established clinical breakpoints (CBPs) for interpreting susceptibility test results for swine Salmonella. This gap made it difficult to reliably determine if a particular Salmonella strain was susceptible, intermediate, or resistant to APR, hindering effective treatment decisions. Furthermore, the impact of APR on the complex gut microbiome of infected and treated piglets was not well understood. This study aims to fill these gaps by defining the CBP for APR against swine Salmonella and investigating the dynamic changes in the ileum microbiota during infection and treatment.

Methods

The researchers employed a multi-pronged approach:

  • Clinical Breakpoint (CBP) Establishment: This involved determining three key values:
  • Wild-Type Cutoff (CO<sub>WT</sub>): Based on the minimum inhibitory concentration (MIC) distribution of susceptible Salmonella strains.
  • Pharmacokinetic/Pharmacodynamic (PK/PD) Cutoff (CO<sub>PD</sub>): Derived from analyzing how drug concentration relates to its effect over time, considering both drug levels in the gut and bacterial killing.
  • Clinical Cutoff (CO<sub>CL</sub>): Based on clinical efficacy data from treatment trials. These values were then integrated using guidelines from the Clinical Laboratory Standards Institute (CLSI) to establish the final CBP.

  • In Vitro and Ex Vivo Antibacterial Assays: Standard MIC and minimum bactericidal concentration (MBC) tests were performed. Additionally, time-killing curves were generated in both laboratory broth and piglet ileum fluid to assess APR's effectiveness under more realistic conditions.

  • Pharmacokinetic (PK) Studies: APR concentrations were measured in the plasma and ileum contents of pigs after oral administration to understand how the drug is absorbed and distributed.
  • 16S rRNA Gene Sequencing: Ileum content samples from piglets at different stages (healthy, infected, treated, recovered, withdrawal) were analyzed using 16S rRNA gene sequencing to characterize the bacterial community composition and diversity.
  • Bioinformatics and Statistical Analysis: Various bioinformatic tools were used for sequence processing, taxonomic classification, diversity analysis (alpha and beta diversity), and correlation network analysis to identify key microbial interactions. LEfSe (Linear Discriminant Analysis Effect Size) was used to identify differentially abundant taxa. KEGG pathway analysis was performed to predict the functional potential of the microbial communities.

Datasets

  • Swine Salmonella Isolates: 185 swine Salmonella strains were used for MIC determination and CO<sub>WT</sub> establishment.
  • Piglet Ileum Content Samples: Samples were collected from piglets at five different time points: before infection, during infection, during APR treatment, during the cure phase, and during the withdrawal period. These were used for 16S rRNA gene sequencing.
  • PK Data: Plasma and ileum content samples from pigs were analyzed for APR concentration.

Key Insights and Ideas

  • Standardizing Antibiotic Use: Establishing a clinical breakpoint for APR is critical for accurate interpretation of susceptibility tests, leading to more informed and effective antibiotic use in veterinary medicine.
  • Gut Microbiome as a Dynamic Ecosystem: The study highlights that the gut microbiome is not static but undergoes significant shifts in response to infection and antibiotic treatment.
  • APR's Targeted Impact: While APR effectively targets Salmonella, it also influences the broader ileum microbial community, with some bacteria being suppressed and others potentially benefiting.
  • Key Bacterial Players: Specific genera like Methanobrevibacter and Prevotella emerged as central to the microbial community's response, acting as "key nodes" in the network.
  • Metabolic Reprogramming: APR treatment and Salmonella infection alter the metabolic functions of the ileum microbiota, impacting pathways like amino acid biosynthesis and metabolism.

Key Results

  • Clinical Breakpoint: The study established the following cutoffs for APR against swine Salmonella in the ileum: CO<sub>WT</sub> = 32 µg/mL, CO<sub>PD</sub> = 32 µg/mL, and CO<sub>CL</sub> = 8 µg/mL. The final clinical breakpoint (CBP) was determined to be 32 µg/mL.
  • Antibacterial Activity: APR demonstrated concentration-dependent bactericidal effects both in vitro and ex vivo in ileum fluid.
  • PK/PD: APR showed limited absorption in plasma but higher concentrations in ileum fluid, suggesting its efficacy for gastrointestinal infections. PK parameters in ileum fluid were deemed more relevant for PK/PD modeling of intestinal infections.
  • Microbiota Shifts:
    • Salmonella infection and APR treatment significantly altered the ileum microbiota composition.
  • The phyla Bacteroidetes and Euryarchaeota showed the most pronounced changes.
  • At the genus level, Methanobrevibacter significantly increased during APR treatment and decreased during the cure and withdrawal phases.
  • Prevotella abundance was significantly lower in treated groups compared to healthy controls.
  • S24-7 decreased after infection and slightly increased after cure.
  • Ruminococcaceae increased after infection and decreased after APR treatment.
  • Key Genera: Methanobrevibacter and Prevotella were identified as key nodes in the microbial co-occurrence network.
  • Metabolic Pathways: The top five KEGG pathways affected were Valine, leucine and isoleucine biosynthesis; D-Glutamine and D-glutamate metabolism; D-Alanine metabolism; Peptidoglycan biosynthesis; and Biosynthesis of amino acids.

Limitations and Future Work

  • MIC<sub>90</sub> Representation: The study notes that while the MIC<sub>90</sub> for 141 out of 185 strains was 8 µg/mL, further investigation is needed to confirm if this accurately represents actual clinical data.
  • Dosage Regimen Specificity: The proposed dosage regimen is specifically for Salmonella-induced Salmonellosis. Further PK/PD studies are required for other organisms.
  • Field Studies: The authors suggest increasing the number of isolates and conducting field distribution studies to further validate the findings and address variability.
  • Metabolite Analysis: Future studies could explore the correlation between key gut microbiome genera and piglet diarrhea by investigating the metabolites produced by these microbes.
  • Broader Impact: While this study focuses on ileum flora, future research could investigate the impact of APR on the entire gut ecosystem, including fecal microbiota.

Summary updated

Abstract

The purpose of this study was to establish the clinical breakpoint (CBP) of apramycin (APR) against <i>Salmonella</i> in swine and evaluate its effect on intestinal microbiota. The CBP was established based on three cutoff values of wild-type cutoff value (CO<sub>WT</sub>), pharmacokinetic-pharmadynamic (PK/PD) cutoff value (CO<sub>PD</sub>) and clinical cutoff value (CO<sub>CL</sub>). The effect of the optimized dose regimen based on ex vivo PK/PD study. The evolution of the ileum flora was determined by the <i>16rRNA</i> gene sequencing and bioinformatics. This study firstly established the CO<sub>WT</sub>, CO<sub>PD</sub> in ileum, and CO<sub>CL</sub> of APR against swine <i>Salmonella</i>, the value of these cutoffs were 32 µg/mL, 32 µg/mL and 8 µg/mL, respectively. According to the guiding principle of the Clinical Laboratory Standards Institute (CLSI), the final CBP in ileum was 32 µg/mL. Our results revealed the main evolution route in the composition of ileum microbiota of diarrheic piglets treated by APR. The change of the abundances of <i>Bacteroidetes</i> and <i>Euryarchaeota</i> was the most obvious during the evolution process. <i>Methanobrevibacter</i>, <i>Prevotella</i>, <i>S24-7</i> and <i>Ruminococcaceae</i> were obtained as the highest abundance genus. The abundance of <i>Methanobrevibacter</i> increased significantly when APR treatment carried and decreased in cure and withdrawal period groups. The abundance of <i>Prevotella</i> in the tested groups was significantly lower than that in the healthy group. A decreased of abundance in <i>S24-7</i> was observed after <i>Salmonella</i> infection and increased slightly after cure. <i>Ruminococcaceae</i> increased significantly after <i>Salmonella</i> infection and decreased significantly after APR treatment. In addition, the genera of <i>Methanobrevibacter</i> and <i>Prevotella</i> were defined as the key node. Valine, leucine and isoleucine biosynthesis, D-Glutamine and D-glutamate metabolism, D-Alanine metabolism, Peptidoglycan and amino acids biosynthesis were the top five Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in the ileum microbiota of piglets during the <i>Salmonella</i> infection and APR treatment process. Our study extended the understanding of dynamic shift of gut microbes during diarrheic piglets treated by APR.
BibTeX
@article{dai2022clinical,
  author = {Xinyu Dai and Yufeng Gu and Jinli Guo and Lingli Huang and Guyue Cheng and Dapeng Peng and Haihong Hao},
  title = {{Clinical Breakpoint of Apramycin to Swine Salmonella and Its Effect on Ileum Flora}},
  journal = {International Journal of Molecular Sciences},
  year = {2022},
  doi = {10.3390/ijms23031424},
}
Figure